WO2010102212A3 - Mimétiques de neurotrophine et leurs utilisations - Google Patents

Mimétiques de neurotrophine et leurs utilisations Download PDF

Info

Publication number
WO2010102212A3
WO2010102212A3 PCT/US2010/026372 US2010026372W WO2010102212A3 WO 2010102212 A3 WO2010102212 A3 WO 2010102212A3 US 2010026372 W US2010026372 W US 2010026372W WO 2010102212 A3 WO2010102212 A3 WO 2010102212A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurotrophin mimetics
compounds
mimetics
neurotrophin
application
Prior art date
Application number
PCT/US2010/026372
Other languages
English (en)
Other versions
WO2010102212A2 (fr
Inventor
Frank M. Longo
Original Assignee
The University Of North Carolina At Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of North Carolina At Chapel Hill filed Critical The University Of North Carolina At Chapel Hill
Priority to CA2754570A priority Critical patent/CA2754570A1/fr
Priority to JP2011553135A priority patent/JP2012519703A/ja
Priority to EP10749395.9A priority patent/EP2403839A4/fr
Publication of WO2010102212A2 publication Critical patent/WO2010102212A2/fr
Publication of WO2010102212A3 publication Critical patent/WO2010102212A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des composés qui sont de nouveaux mimétiques de neurotrophine. L'invention porte également sur le traitement de troubles associés à l'expression de p75, tels que la dégradation ou le dysfonctionnement de cellules exprimant p75 chez un mammifère, par administration d'une quantité efficace de tels composés.
PCT/US2010/026372 2009-03-06 2010-03-05 Mimétiques de neurotrophine et leurs utilisations WO2010102212A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2754570A CA2754570A1 (fr) 2009-03-06 2010-03-05 Mimetiques de neurotrophine et leurs utilisations
JP2011553135A JP2012519703A (ja) 2009-03-06 2010-03-05 ニューロトロフィン・ミメティック及びその使用
EP10749395.9A EP2403839A4 (fr) 2009-03-06 2010-03-05 Mimétiques de neurotrophine et leurs utilisations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15830609P 2009-03-06 2009-03-06
US61/158,306 2009-03-06
US16428209P 2009-03-27 2009-03-27
US61/164,282 2009-03-27

Publications (2)

Publication Number Publication Date
WO2010102212A2 WO2010102212A2 (fr) 2010-09-10
WO2010102212A3 true WO2010102212A3 (fr) 2011-03-31

Family

ID=42710232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/026372 WO2010102212A2 (fr) 2009-03-06 2010-03-05 Mimétiques de neurotrophine et leurs utilisations

Country Status (4)

Country Link
EP (1) EP2403839A4 (fr)
JP (2) JP2012519703A (fr)
CA (1) CA2754570A1 (fr)
WO (1) WO2010102212A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2586445A1 (fr) 2005-04-15 2013-05-01 University Of North Carolina At Chapel Hill Procédés permettant de faciliter la survie de cellules à l'aide de mimétiques de neurotrophine
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
AU2010319349B2 (en) 2009-11-12 2015-07-16 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2012048417A1 (fr) * 2010-10-13 2012-04-19 Horacio Uri Saragovi Inhibiteurs du récepteur p75 et leurs utilisations
WO2014052659A1 (fr) * 2012-09-27 2014-04-03 Pharmatrophix, Inc. Formes cristallines de composés mimétiques de la neurotrophine et leurs sels
WO2018039641A1 (fr) * 2016-08-25 2018-03-01 Pharmatrophix, Inc. Procédés et composés pour le traitement de troubles d'utilisation d'alcool et de maladies associées

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047863A1 (fr) * 1997-04-22 1998-10-29 Chiesi Farmaceutici S.P.A. DERIVES D'AMINO-ACIDES INHIBITEURS DES METALLOPROTEASES DE LA MATRICE EXTRACELLULAIRE ET DE LA LIBERATION DU TNF $g(a)
WO2003006423A1 (fr) * 2001-07-11 2003-01-23 Elan Pharmaceuticals, Inc. Composes de n-(3-amino-2-hydroxy-propyl) alkylamide substitues
WO2003040096A2 (fr) * 2001-11-08 2003-05-15 Elan Pharmaceuticals, Inc. Derives 1,3-diamino-2-hydroxypropane n-n'-substitues
US20080221147A1 (en) * 1999-05-17 2008-09-11 Ross Gregory M Method of inhibiting neurotrophin-receptor binding

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2586445A1 (fr) * 2005-04-15 2013-05-01 University Of North Carolina At Chapel Hill Procédés permettant de faciliter la survie de cellules à l'aide de mimétiques de neurotrophine
WO2008107365A1 (fr) * 2007-03-02 2008-09-12 Medivir Ab Nouveaux composés

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047863A1 (fr) * 1997-04-22 1998-10-29 Chiesi Farmaceutici S.P.A. DERIVES D'AMINO-ACIDES INHIBITEURS DES METALLOPROTEASES DE LA MATRICE EXTRACELLULAIRE ET DE LA LIBERATION DU TNF $g(a)
US20080221147A1 (en) * 1999-05-17 2008-09-11 Ross Gregory M Method of inhibiting neurotrophin-receptor binding
WO2003006423A1 (fr) * 2001-07-11 2003-01-23 Elan Pharmaceuticals, Inc. Composes de n-(3-amino-2-hydroxy-propyl) alkylamide substitues
WO2003040096A2 (fr) * 2001-11-08 2003-05-15 Elan Pharmaceuticals, Inc. Derives 1,3-diamino-2-hydroxypropane n-n'-substitues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AZARYAN,L.V. ET AL.: "Synthesis and anticonvulsant activity of aminoalkyl derivatives of 5-(p-alkoxyphenyl)-5-methylhydantoins", KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 18, no. 5, 1984, pages 568 - 572, XP008164576 *
ORAZI,0.0. ET AL.: "Substitution in the hydantoin ring- I. Aminomethylation", TETRAHEDRON, vol. 15, 1961, pages 93 - 99, XP008164659 *
See also references of EP2403839A4 *

Also Published As

Publication number Publication date
EP2403839A4 (fr) 2014-05-28
EP2403839A2 (fr) 2012-01-11
JP2012519703A (ja) 2012-08-30
WO2010102212A2 (fr) 2010-09-10
JP2016026142A (ja) 2016-02-12
CA2754570A1 (fr) 2010-09-10

Similar Documents

Publication Publication Date Title
WO2009089494A3 (fr) Compositions pharmaceutiques
JOP20180019A1 (ar) بيرولات [3، 4-سي] اوكتاهيدروبيرولو ثنائية الاستبدال كمعدلات لمستقبل اوريكسين
WO2008103470A3 (fr) Composés létaux dépendants du signal de ras oncogénique
WO2008070692A3 (fr) Composés chimiques et leurs utilisations
WO2012106281A3 (fr) Molécules trail multimodales et leurs utilisations en thérapies cellulaires
WO2009020802A3 (fr) Traitement de l'obésité
WO2011084808A3 (fr) Compositions de polypeptides bifonctionnels et procédés pour le traitement de maladies métaboliques et cardiovasculaires
WO2011035335A3 (fr) Compositions d'adamts13 liquides stabilisées et lyophilisées
WO2009089635A9 (fr) Traitement de maladies neurodégénératives avec de la progranuline (pgrn)
WO2007005300A3 (fr) Traitement de la keratoconjonctivite seche
PL2440073T3 (pl) Synergistyczna mieszanina beta-galakto-oligosacharydów z wiązaniami beta-1,3 i beta-1,4/1,6
WO2011083150A3 (fr) Petites molécules pour traiter l'obésité
WO2010102212A3 (fr) Mimétiques de neurotrophine et leurs utilisations
WO2011066544A3 (fr) Composés deutériés utiles pour le traitement de maladies neurodégénératives
WO2006048242A3 (fr) Utilisation de pirlindole pour traiter des maladies caracterisees par une proliferation de lymphocytes t et/ou une hyperproliferation de keratinocytes, en particulier une dermatite atopique et un psoriasis
WO2012078902A3 (fr) Régulateurs de la protéostasie
UY32497A (es) "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso"
WO2009111317A3 (fr) Administration endoscopique de lumière rouge/proche infrarouge à la substance noire pour traiter la maladie de parkinson
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
WO2012015758A3 (fr) Méthodes de traitement de la douleur
WO2008070268A3 (fr) Compositions pharmaceutiques
EP2180896A4 (fr) Composition pour le diagnostic, la prévention ou le traitement de maladies liées à l'expression il-8 ou gro-alpha de cellules, comprenant des cellules souches mésenchymateuses ucb
WO2011091366A3 (fr) Procédés de traitement ou de prévention de la parodontite et maladies associées à la parodontite
WO2009143387A3 (fr) Modulation de l’expression de smrt
WO2012025902A3 (fr) Utilisation de sucres dans une matrice de stabilisation et des compositions solides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10749395

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011553135

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2754570

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010749395

Country of ref document: EP